Table II.
Number of immune cells in the peripheral blood of patients following each course of CIK treatment.
| Following CIK treatment (course, n) | |||||
|---|---|---|---|---|---|
| Cells | Prior to CIK treatment | 1 | 2 | 3 | 4 |
| CD3+CD4+ (%) | |||||
| CIK group | 34.4±9.3 | 28.7±8.8 | 31.7±10.7 | 36.7±4.9 | 41.3±9.3a |
| Che-Sur group | 38.8±8.8 | 41.7±10.5 | 48.2±8.7a | 40.5±5.9 | 44.5±2.9 |
| Che-Rad group | 26.4±7.6 | 26.1±7.4 | 26.0±9.4 | 24.6±5.9 | 24.5±5.0 |
| P-valueb | 0.002 | 0.005 | 0.008 | 0.038 | 0.002 |
| CD3+ (%) | |||||
| CIK group | 62.7±9.3 | 55.4±9.0 | 63.0±13.1 | 77.4±7.3a | 79.8±6.6a |
| Che-Sur group | 69.9±6.9 | 70.8±8.6 | 75.9±4.7a | 69.5±9.1 | 78.5±1.8a |
| Che-Rad group | 68.0±11.8 | 65.4±12.6 | 68.3±15.3 | 64.6±12.2 | 66.2±12.7 |
| P-valueb | 0.187 | 0.051 | 0.173 | 0.206 | 0.168 |
| CD3−CD16+56+ (NK) (%) | |||||
| CIK group | 18.8±9.1 | 18.0±7.0 | 22.5±5.7 | 24.1±4.9 | 19.4±5.9 |
| Che-Sur group | 19.7±9.4 | 19.4±9.2 | 18.1±10.1 | 18.3±12.5 | 19.5±14.0 |
| Che-Rad group | 23.7±12.9 | 27.1±9.8 | 22.3±12.1 | 26.4±12.3 | 20.3±7.5 |
| P-valueb | 0.514 | 0.027 | 0.643 | 0.381 | 0.993 |
| CD3+CD16+56+ (NKT) (%) | |||||
| CIK group | 11.5±5.4 | 12.0±7.2 | 10.6±5.6 | 14.3±3.9 | 12.4±6.4 |
| Che-Sur group | 4.9±2.4 | 6.6±4.7 | 5.6±3.2 | 6.3±3.0 | 8.4±4.0a |
| Che-Rad group | 10.9±9.2 | 10.9±11.9 | 11.2±9.7 | 10.3±12.0 | 7.7±4.4 |
| P-valueb | 0.019 | 0.385 | 0.222 | 0.513 | 0.437 |
a
P<0.05 vs. control in the same treatment group compared with different CIK treatment courses.
b
P<0.05 vs. control in same CIK treatment course compared with different treatment groups. CIK, cytokine-induced killer; CD, cluster of differentiation; NK, natural killer.